News In blink-and-miss-it moment, Harris vows to expand OOP cap The US Presidential debate barely mentioned pharma topics, but Harris did have one notable sound bite toward the very end of the night.
News Neurogene falls again on Rett gene therapy side effects Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.